MetaCap

Contineum Therapeutics (CTNM) vs Inovio Pharmaceuticals (INO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Inovio Pharmaceuticals (INO) has outperformed Contineum Therapeutics (CTNM) over the past year, gaining 0.0% versus a loss of 20.7%. Contineum Therapeutics is the larger company by market cap ($340.8 million vs $329.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTNM-20.69%INO0.00%
+67%-3%-72%
Nov 21, 20251 yearNov 20, 2026
CTNM-43.64%INO-85.08%
+43%-29%-101%
Apr 1, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTNM versus INO key metrics
MetricCTNMINO
Share price$8.68$1.76
Market cap$340.83M$329.66M
1-day change-3.98%+2.92%
YTD return-24.06%+1.15%
1-year return-20.69%0.00%
5-year return—-97.98%
EPS (TTM)$-1.77$-0.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$65.34K
Revenue growth (YoY)—-69.99%
Net income (latest FY)$-59.98M$-84.95M
Operating margin—-132871.32%
Net margin—-130000.00%
52-week high$17.79$2.72
52-week low$6.73$0.56
Distance from 52-week high-51.19%-35.29%
Analyst consensusbuystrong_buy
Avg. price target upside+146.89%+259.66%
Average volume776.03K11.24M
Shares outstanding35.35M187.31M
Employees51112
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INO has outperformed CTNM by 20.7 percentage points over the past year.

About Contineum Therapeutics

CTNM stock →

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.

Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees

About Inovio Pharmaceuticals

INO stock →

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees

CTNM vs INO FAQ

Which is bigger, Contineum Therapeutics or Inovio Pharmaceuticals?

Contineum Therapeutics (CTNM) is larger, with a market capitalization of $340.83M compared with $329.66M for Inovio Pharmaceuticals (INO).

Which stock has performed better over the past year, CTNM or INO?

INO returned 0.00% over the past 12 months, compared with -20.69% for CTNM (price return, excluding dividends). Past performance does not predict future results.

Are Contineum Therapeutics and Inovio Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons